Compare Modine Manufacturing Company (MOD) vs Summit Therapeutics Inc (SMMT) Price & Performance

Modine Manufacturing (MOD) trades at $192.35, down 1.19% on the day, with a bearish technical signal despite strong analyst support. The company shows robust revenue growth driven by data center cooling demand, with Q2 2026 EPS beating estimates at $1.53 versus $1.30 expected. However, valuation metrics appear stretched with a P/E of 71.77 and EV/EBITDA of 35.15, while profit margins face pressure from supply chain constraints.

The outlook remains positive due to strong data center backlog growth and analyst consensus price target of $305, representing 59% upside potential. Key risks include execution challenges in scaling production and margin compression. With 77% of analysts rating MOD as Buy and no Sell ratings, Wall Street maintains bullish sentiment despite near-term volatility.

Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.

The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.